<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104087">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01760161</url>
  </required_header>
  <id_info>
    <org_study_id>20120042</org_study_id>
    <nct_id>NCT01760161</nct_id>
  </id_info>
  <brief_title>Bilateral Dual Transversus Abdominis Plane Block for Robotic Assisted Laparoscopic Surgery</brief_title>
  <official_title>A Randomised, Double-blind Study to Evaluate the Effect of Bilateral Dual Transversus Abdominis Plane Block on Postoperative Pain and Plasma Concentration of Ropivacaine After Robotic Assisted Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg Universityhospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg Universityhospital</source>
  <oversight_info>
    <authority>Denmark: The Danish National Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of bilateral dual transversus abdominis plane block on postoperative
      pain after robotic assited laparoskopic surgery and measure the plasma-level of ropivacain
      after the bilateral dual transversus abdominis plane block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After randomisation patients for robotic assisted laparoscopic surgery will receive
      bilateral dual transversus abdominis plane block containing either ropivacain or isotonic
      potassium chloride.

      The investigators will record pain-score, opioid-consumption and sensibility on the
      abdominal wall in the postoperative periode.

      Also a blood sample will be taken at 15, 30, 60, 120 and 240 minutes after the block in
      order to measure the plasma-level of ropivacain after bilateral dual transversus abdominis
      plane block.

      The investigators assume that there will be significant effect on postoperative pain and
      that the level of plasma-ropivacain will be acceptable.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain-score on numerical rating scale</measure>
    <time_frame>4 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Administration of opioids</measure>
    <time_frame>The first 24 hours after surgery.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-score on numerical rating scale</measure>
    <time_frame>8 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-score on numerical rating scale</measure>
    <time_frame>24 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Thermoanalgesia at dermatome-level th6-th12</measure>
    <time_frame>1 hour after bilateral dual transversus abdominis plane block</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Plasma-ropivacain level</measure>
    <time_frame>15, 30, 60, 120 and 240 mins after the block</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pain Treatment</condition>
  <condition>Robotic Assisted Laparoscopic Surgery</condition>
  <condition>Bilateral Dual Transversus Abdominis Plane Block</condition>
  <arm_group>
    <arm_group_label>Ropivacain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic potassium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block</description>
    <arm_group_label>Ropivacain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic potassium chloride</intervention_name>
    <description>Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.</description>
    <arm_group_label>Isotonic potassium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled for robotic assisted laparoscopis surgery

          -  acceptance to participate

        Exclusion Criteria:

          -  allergies to local analgetics

          -  daily use of strong opioids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nils Bjerregaard, M.D.</last_name>
    <phone>004522860649</phone>
    <email>niheb@rn.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Region Nord</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nils Bjerregaard, M.D</last_name>
      <phone>004522860649</phone>
      <email>niheb@rn.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 2, 2013</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg Hospital</investigator_affiliation>
    <investigator_full_name>Nils Bjerregaard</investigator_full_name>
    <investigator_title>Consultant Anestetist</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>opioid consumption</keyword>
  <keyword>termanalgesia</keyword>
  <keyword>plasmaropivacain level</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
